Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.
Yasuo YanagiKanji TakahashiTomohiro IidaFumi GomiHiroshi OnishiJunko MoriiTaiji SakamotoPublished in: Ophthalmology and therapy (2024)
Ranibizumab biosimilar was demonstrated as a cost-saving option compared to aflibercept across all subtypes of nAMD, irrespective of the perspectives considered.